Cover Image

Mechanism Underlying Triple VEGFR Inhibitor Tivozanib-Induced Hypertension in Mice Model

Tivozanib is a triple vascular endothelial growth factor receptor inhibitor, recently approved for the treatment of refractory advanced renal cell carcinoma. Clinical studies showed that around 46% of patients who received tivozanib suffer from hypertension in all grades. Thus, the present study was...

Full description

Saved in:

Bibliographic Details
Main Authors:	Wael A. Alanazi (Author), Abdulrahman S. Alanazi (Author), Doaa M. El-Nagar (Author), Abdullah M. Aljuraybah (Author), Sary Alsanea (Author), Metab Alharbi (Author)
Format:	Book
Published:	MDPI AG, 2023-02-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Angiotensin II type 1 receptor blockade attenuates gefitinib-induced cardiac hypertrophy via adjusting angiotensin II-mediated oxidative stress and JNK/P38 MAPK pathway in a rat model
by: Wael A. Alanazi, et al.
Published: (2022)

Design, synthesis, docking, ADMET studies, and anticancer evaluation of new 3-methylquinoxaline derivatives as VEGFR-2 inhibitors and apoptosis inducers
by: Mohammed M. Alanazi, et al.
Published: (2021)

Dapagliflozin Mitigates Hypotension in Lipopolysaccharide-Induced Acute Inflammation Independent of Glycemia Level
by: Wael A. Alanazi, et al.
Published: (2023)

Profile of tivozanib and its potential for the treatment of advanced renal cell carcinoma
by: Cowey CL
Published: (2013)

Discovery of new VEGFR-2 inhibitors based on bis([1, 2, 4]triazolo)[4,3-a:3',4'-c]quinoxaline derivatives as anticancer agents and apoptosis inducers
by: Nawaf A. Alsaif, et al.
Published: (2021)

Pharmacokinetic profile of sildenafil citrate in healthy Middle Eastern Males: Comparison with other ethnicities
by: Abdulrahman Alwhaibi, et al.
Published: (2021)

Synthesis, anticancer, apoptosis-inducing activities and EGFR and VEGFR2 assay mechanistic studies of 5,5-diphenylimidazolidine-2,4-dione derivatives: Molecular docking studies
by: Hamad M. Alkahtani, et al.
Published: (2019)

A real-world disproportionality analysis of Tivozanib data mining of the public version of FDA adverse event reporting system
by: Kaixuan Wang, et al.
Published: (2024)

Resibufogenin Suppresses Triple-Negative Breast Cancer Angiogenesis by Blocking VEGFR2-Mediated Signaling Pathway
by: Ting Yang, et al.
Published: (2021)

Butin Attenuates Arthritis in Complete Freund's Adjuvant-Treated Arthritic Rats: Possibly Mediated by Its Antioxidant and Anti-Inflammatory Actions
by: Sami I. Alzarea, et al.
Published: (2022)

Discovery of new 3-methylquinoxalines as potential anti-cancer agents and apoptosis inducers targeting VEGFR-2: design, synthesis, and in silico studies
by: Mohammed M. Alanazi, et al.
Published: (2021)

Discovery of a highly selective VEGFR2 kinase inhibitor CHMFL-VEGFR2-002 as a novel anti-angiogenesis agent
by: Zongru Jiang, et al.
Published: (2020)

Gastroprotective evaluation of Medicago sativa L. (Fabaceae) on diabetic rats
by: Phool Chandra, et al.
Published: (2023)

Comparison of small molecules VEGFR inhibitors in the treatment of renal cell carcinoma
by: Jie Yi Tan, et al.
Published: (2023)

Recent advances of anti-angiogenic inhibitors targeting VEGF/VEGFR axis
by: Lei Wang, et al.
Published: (2024)

Discovery of sulfonamide-tethered isatin derivatives as novel anticancer agents and VEGFR-2 inhibitors
by: Moataz A. Shaldam, et al.
Published: (2023)

New benzothiazole hybrids as potential VEGFR-2 inhibitors: design, synthesis, anticancer evaluation, and in silico study
by: Mohammad M. Al-Sanea, et al.
Published: (2023)

Vascular Endothelial Growth Factor Receptor (VEGFR-2)/KDR Inhibitors: Medicinal Chemistry Perspective
by: Siddharth J. Modi, et al.
Published: (2019)

New Series of VEGFR-2 Inhibitors and Apoptosis Enhancers: Design, Synthesis and Biological Evaluation
by: Abdallah AE, et al.
Published: (2022)

Immunohistochemical study of VEGF-A, VEGFR-1, VEGFR-2 and CD34 expression in сolorectal adenocarcinoma progression
by: M. A. Shyshkin
Published: (2019)

Ceftriaxone and MC-100093 mitigate fentanyl-induced cardiac injury in mice: Preclinical investigation of its underlying molecular mechanisms
by: Abdullah F. AlAsmari, et al.
Published: (2024)

Virtual screening of anticancer activity of chalcones and pyrazolines as potential EGFR, VEGFR, and cytochrome P450 inhibitors
by: Hesti Lina Wiraswati, et al.
Published: (2023)

VEGFR-2 inhibitors and apoptosis inducers: synthesis and molecular design of new benzo[g]quinazolin bearing benzenesulfonamide moiety
by: Mostafa M. Ghorab, et al.
Published: (2017)

In Vitro Anticancer Activity Screening of Novel Fused Thiophene Derivatives as VEGFR-2/AKT Dual Inhibitors and Apoptosis Inducers
by: Rana M. Abdelnaby, et al.
Published: (2022)

Design, synthesis, and screening of ortho-amino thiophene carboxamide derivatives on hepatocellular carcinomaas VEGFR-2Inhibitors
by: Mohammed K. AbdElhameid, et al.
Published: (2018)

Novel NO-TZDs and trimethoxychalcone-based DHPMs: design, synthesis, and biological evaluation as potential VEGFR-2 inhibitors
by: Mater H. Mahnashi, et al.
Published: (2024)

Benzoxazole derivatives as new VEGFR-2 inhibitors and apoptosis inducers: design, synthesis, in silico studies, and antiproliferative evaluation
by: Mohammed S. Taghour, et al.
Published: (2022)

Design, Synthesis, Molecular Modeling, and Anticancer Evaluation of New VEGFR-2 Inhibitors Based on the Indolin-2-One Scaffold
by: Mohamed A. Abdelgawad, et al.
Published: (2022)

Synthesis, biological evaluation, and molecular docking of new series of antitumor and apoptosis inducers designed as VEGFR-2 inhibitors
by: Abdallah E. Abdallah, et al.
Published: (2022)

Novel thienopyrimidine derivatives as dual EGFR and VEGFR-2 inhibitors: design, synthesis, anticancer activity and effect on cell cycle profile
by: Aml E.-S. Mghwary, et al.
Published: (2019)

Anti-cancer and immunomodulatory evaluation of new nicotinamide derivatives as potential VEGFR-2 inhibitors and apoptosis inducers: in vitro and in silico studies
by: Reda G. Yousef, et al.
Published: (2022)

Potential Anticancer Lipoxygenase Inhibitors from the Red Sea-Derived Brown Algae <i>Sargassum cinereum</i>: An In-Silico-Supported In-Vitro Study
by: Sami I. Alzarea, et al.
Published: (2021)

Reversal of TGF-β-induced epithelial-mesenchymal transition in hepatocellular carcinoma by sorafenib, a VEGFR-2 and Raf kinase inhibitor
by: Siddharth J. Modi, et al.
Published: (2021)

Novel N-Arylmethyl-aniline/chalcone hybrids as potential VEGFR inhibitors: synthesis, biological evaluations, and molecular dynamic simulations
by: Hesham Haffez, et al.
Published: (2023)

Is there an epigenetic component underlying the resistance of triple-negative breast cancers to PARP inhibitors?
by: Amanda eLovato, et al.
Published: (2012)

Attitudes and practices of infection control among dental students at colleges of dentistry, Al-Qassim Region in the Saudi Arabia
by: Alnashmi Obaid Alanazi, et al.
Published: (2019)

Design, synthesis, anticancer evaluation, and molecular modelling studies of novel tolmetin derivatives as potential VEGFR-2 inhibitors and apoptosis inducers
by: Asmaa E. Kassab, et al.
Published: (2021)

Design, Synthesis, and Biological Evaluation of a Novel VEGFR-2 Inhibitor Based on a 1,2,5-Oxadiazole-2-Oxide Scaffold with MAPK Signaling Pathway Inhibition
by: Mater H. Mahnashi, et al.
Published: (2022)

Design, synthesis, antitumor evaluation, and molecular docking of novel pyrrolo[2,3-d]pyrimidine as multi-kinase inhibitors
by: Ashwag S. Alanazi, et al.
Published: (2023)

Vascular endothelial growth factor and its soluble receptors VEGFR-1 and VEGFR-2 in the serum of patients with systemic lupus erythematosus
by: Ewa Robak, et al.
Published: (2003)